

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(withdrawn):** A method for stabilizing an antibody in a solution, which comprises adding glycine and citric acid to the antibody in said solution.
2. **(withdrawn):** The method according to Claim 1, wherein the method of stabilizing suppresses formation of a soluble association and a chemically degraded product of the antibody in the solution.
3. **(withdrawn):** A method for suppressing the formation of a soluble association of an antibody in a solution, which comprises adding glycine to the antibody in said solution.
4. **(withdrawn):** A method for suppressing the formation of a chemically degraded product of an antibody in a solution, which comprises adding citric acid to the antibody in said solution.
5. **(withdrawn):** The method according to any one of Claims 1 to 4, wherein concentration of the antibody in said solution is from 0.01 to 150 mg/mL.
6. **(withdrawn):** The method according to any one of Claims 1 to 3, wherein concentration of glycine in said solution is from 10 to 30 mg/mL.

7. **(withdrawn):** The method according to any one of Claims 1, 2 and 4, wherein concentration of citric acid in said solution is from 0.1 to 50 mmol/L.
8. **(withdrawn):** The method according to Claim 2, wherein the concentration of the antibody in said solution is 0.01 to 150 mg/mL, the concentration of glycine in said solution is 10 to 30 mg/mL and the concentration of citric acid in said solution is 0.1 to 50 mg/mL, said solution further comprising a nonionic surfactant.
9. **(withdrawn):** The method according to Claim 8, wherein the pH of the solution is within the range of 4 to 7.
10. **(withdrawn):** The method according to Claim 9, wherein the antibody is a humanized antibody or a human antibody.
11. **(withdrawn):** The method according to Claim 10, wherein the antibody is an antibody to ganglioside GD3 or an antibody to CCR4.
- 12-13. **(canceled).**
14. **(currently amended):** A solution-type antibody preparation comprising ~~the an~~ antibody, and an effective amount of glycine and citric acid to suppress formation of a soluble solution, a chemically degraded product and an insoluble aggregate of the antibody.

15. (currently amended): The preparation according to ~~any one of Claims 12 to Claim~~ 14, wherein the antibody concentration is 0.01 to 150 mg/mL.

16. (previously presented): The preparation according to Claim 15, wherein the glycine concentration is 10 to 30 mg/mL.

17. (previously presented): The preparation according to Claim 15, wherein the citric acid concentration is 0.1 to 50 mmol/L.

18. (currently amended): The preparation according to ~~Claim 16~~ Claim 15, wherein the citric acid concentration is 0.1 to 50 mmol/L, and further comprising a nonionic surfactant.

19. (currently amended): The preparation according to Claim 18, wherein said preparation has a pH of the solution ~~is from~~ between 4 ~~to~~ and 7.

20. (previously presented): The preparation according to Claim 19, wherein the antibody is a humanized antibody or a human antibody.

21. (previously presented): The preparation according to Claim 20, wherein the antibody is an antibody to ganglioside GD3 or antibody to CCR4.

22-25. (canceled).